ABP 980, a trastuzumab biosimilar in combination with pertuzumab

Hans-Christian Kolberg, MD, Marien Hospital Bottrop, Bottrop, Germany, discusses evidence of the use of ABP 980, a trastuzumab biosimilar, in patients with HER2+ breast cancer. ABP 980 is approved in the U.S based on extrapolation of data from the LILAC trial, a randomized, double-blind, active-controlled study (NCT01901146) investigating the safety of ABP 980 in women with HER2+ early breast cancer. Results discussed by Dr Kolberg highlight the synergistic activity of ABP 980 which is found to be comparable to that of trastuzumab in combination with pertuzumab and with pertuzumab and docetaxel. This interview took place during the 17th St. Gallen International Breast Cancer Conference.